The stock of INNOVUS PHARMACEUTICALS INC (OTCMKTS:INNV) registered an increase of 73.33% in short interest. INNV’s total short interest was 2,600 shares in November as published by FINRA. Its up 73.33% from 1,500 shares, reported previously. With 8,700 shares average volume, it will take short sellers 0 days to cover their INNV’s short positions.
The stock increased 5.11% or $0.09 during the last trading session, reaching $1.85. About 1,032 shares traded. Innovus Pharmaceuticals, Inc. (OTCMKTS:INNV) has 0.00% since November 7, 2018 and is . It has by 0.00% the S&P500.
Innovus Pharmaceuticals, Inc., a pharmaceutical company, engages in the commercialization, licensing, and development of non-prescription medicine and consumer care products in the United States. The company has market cap of $4.87 million. The Company’s products include Zestra, a proprietary blend of essential oils to enhance desire, arousal, and satisfaction in women; EjectDelay, an over-the-counter monograph-compliant benzocaine gel for premature ejaculation; Sensum+, a non-medicated cream that enhances penile sensitivity; Zestra Glide, a water longer lasting lubricant; Vesele, a proprietary oral supplement of Arginine sexual and cognitive functions; and Androferti, a natural supplement to support overall male reproductive health and sperm quality. It currently has negative earnings. The firm also offers Beyond Human testosterone booster, Ketones, krill oil, Omega 3 fish oil, Vision Formula, blood sugar, colon cleanse, green coffee extract, and growth agent; RecalMax for brain health; and UriVarx, a proprietary supplement for overactive bladder and urinary incontinence.
More notable recent Innovus Pharmaceuticals, Inc. (OTCMKTS:INNV) news were published by: Seekingalpha.com which released: “Innovus Testosterone Booster capsules OK’d in Canada – Seeking Alpha” on February 28, 2019, also Seekingalpha.com with their article: “Western Pacific Hits High Grade Silver At Deer Trail – Seeking Alpha” published on October 09, 2014, Seekingalpha.com published: “Innovus Pharma’ Diabasens OK’d in Canada – Seeking Alpha” on March 01, 2019. More interesting news about Innovus Pharmaceuticals, Inc. (OTCMKTS:INNV) were released by: Seekingalpha.com and their article: “Innovus Pharma sees Q1 2019 revenue of ~$5.4M – Seeking Alpha” published on May 06, 2019 as well as Seekingalpha.com‘s news article titled: “Innovus Pharmaceuticals (INNV) Investor Presentation – Slideshow – Seeking Alpha” with publication date: June 19, 2017.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.